Inhibrx’s (INBX) Market Perform Rating Reiterated at JMP Securities

JMP Securities reiterated their market perform rating on shares of Inhibrx (NASDAQ:INBX) in a research report sent to investors on Thursday,Benzinga reports.

Inhibrx Stock Performance

Shares of INBX opened at $12.33 on Thursday. Inhibrx has a 12-month low of $10.80 and a 12-month high of $34.71. The stock’s 50-day moving average price is $12.64 and its 200 day moving average price is $13.65.

Inhibrx (NASDAQ:INBX) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($2.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.55) by ($0.25). Equities analysts predict that Inhibrx will post 104.88 EPS for the current year.

Hedge Funds Weigh In On Inhibrx

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. PNC Financial Services Group Inc. bought a new stake in shares of Inhibrx in the 4th quarter valued at approximately $28,000. Natixis bought a new stake in shares of Inhibrx in the 4th quarter valued at approximately $31,000. China Universal Asset Management Co. Ltd. bought a new stake in shares of Inhibrx in the 4th quarter valued at approximately $47,000. New York State Common Retirement Fund bought a new stake in shares of Inhibrx in the 4th quarter valued at approximately $53,000. Finally, State of Wyoming bought a new stake in shares of Inhibrx in the 4th quarter valued at approximately $83,000. 82.46% of the stock is currently owned by institutional investors.

About Inhibrx

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.